Expanding Options for Patients There is promising news for adults living with Essential Thrombocythemia (ET). The U.S. Food and Drug Administration (FDA) has officially approved Besremi (ropeginterferon alfa-2b-njft) as a treatment option for adults diagnosed with this rare blood disorder. This approval marks a significant development in the therapeutic landscape for those managing ET. Understanding…